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Abstract
Fumonisin esterase produced from a genetically modiﬁed strain of Komagataella phafﬁ is intended to
degrade fumonisin mycotoxins contaminants in feeds for pigs and poultry. The production strain and its
recombinant genes are not present in the ﬁnal product. The applicant selected 300 U/kg feed to
represent a likely upper limit. This concentration showed to be safe for piglets, chickens and turkeys for
fattening and laying hens; the additive is thus safe for those categories. This conclusion is extended to all
pigs, chickens reared for laying and turkeys reared for breeding and extrapolated to all other poultry
species for growing and laying and to minor porcine species. No evidence of mutagenicity or genotoxicity
was detected and no evidence of toxicity from a repeated-dose oral toxicity study; the residue
assessment did not identify any concern. The use of the additive is, thus, considered safe for consumers.
The additive is not toxic by inhalation and the respiratory exposure is likely to be low; however, a risk of
sensitisation via the respiratory route cannot be excluded. The additive is non-irritant to skin and eyes
and is not considered a dermal sensitiser. No risks for the environment are expected following the use of
the additive in feeds under the proposed condition of use. The additive has the capacity to degrade
fumonisin contaminants in feed of marketable quality when used at the minimum recommended dose of
10 U/kg complete feed, as shown in studies with chickens for fattening, laying hens and weaned piglets.
Since the mode of action of the additive can be reasonably assumed to be the same in animal species for
which the application is made, the Panel on Additives and Products or Substances used in Animal Feed
(FEEDAP) considers the additive efﬁcacious for all poultry and all pigs.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with Article 7.
The European Commission received a request from Biomin GmbH2 for authorisation of the product
fumonisin esterase (FUMzyme®), when used as a feed additive for all pigs and all avian species
(category: technological additives; functional group: substances for reduction of the contamination of
feed by mycotoxins).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the application
to the European Food Safety Authority (EFSA) as an application under Article 4(1) (authorisation of a feed
additive or new use of a feed additive). EFSA received directly from the applicant the technical dossier in
support of this application. The particulars and documents in support of the application were considered
valid by EFSA as of 2 March 2017.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether the
feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the
safety for the target animals, consumer, user and the environment and on the efﬁcacy of the product
fumonisin esterase (FUMzyme®), when used under the proposed conditions of use (see Section 3.1.7).
1.2. Additional information
The product under assessment is an enzyme-based additive intended to degrade fumonisin
mycotoxins found as contaminants of feed. The safety and efﬁcacy of the enzyme expressed in a
different host from that used in the present application were the subjects of two previous opinions: the
ﬁrst, published in 2014, considered its use in feeds for pigs (EFSA FEEDAP Panel, 2014) and the second in
2016 its use in feed for all avian species (EFSA FEEDAP Panel, 2016). This additive is currently authorised
for use in pigs3 and avian species (1m03).4
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier5 in support of the authorisation request for the use of FUMzyme® as a feed additive. The
technical dossier was prepared following the provisions of Article 7 of Regulation (EC) No 1831/2003,
Regulation (EC) No 429/20086 and the applicable EFSA guidance documents.
The FEEDAP Panel used the data provided by the applicant together with data from other sources,
such as previous risk assessments by EFSA or other expert bodies.
EFSA has veriﬁed the European Union Reference Laboratory (EURL) report as it relates to the
methods used for the control of the fumonisin esterase (EC 3.1.1.87) (FUMzyme®) in animal feed. The
Executive Summary of the EURL report can be found in Annex A.7
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 Biomin GmbH, Erber Campus 1, 3131 Getzersdorf, Austria.
3 Commission Implementing Regulation (EU) No 1115/2014 of 21 October 2014 concerning the authorisation of a preparation of
fumonisin esterase produced by Komagataella pastoris (DSM 26643) as a feed additive for pigs. OJ L 302, 22.10.2014, p. 51.
4 Commission Implementing Regulation (EU) 2017/913 of 29 May 2017 concerning the authorisation of a preparation of fumonisin
esterase produced by Komagataella pastoris (DSM 26643) as a feed additive for all avian species. OJ L 139, 30.5.2017, p. 33.
5 FEED dossier reference: FAD-2017-0005.
6 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
7 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/jrcsh/files/ﬁnrep_fad-2017-0005_fumzyme.pdf
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2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of FUMzyme® is
in line with the principles laid down in Regulation (EC) No 429/2008 and the relevant guidance
documents: Guidance on technological additives (EFSA FEEDAP Panel, 2012a), Technical guidance:
Tolerance and efﬁcacy studies in target animals (EFSA FEEDAP Panel, 2011), Technical Guidance for
assessing the safety of feed additives for the environment (EFSA, 2008), Guidance for establishing the
safety of additives for the consumer (EFSA FEEDAP Panel, 2012b), Guidance on studies concerning the
safety of use of the additive for users/workers (EFSA FEEDAP Panel, 2012c).
3. Assessment
The present application concerns an additive containing the enzyme fumonisin esterase as the
single active agent intended for use as a technological additive (functional group substances for
reduction of the contamination of feed by mycotoxins).
3.1. Characterisation
3.1.1. Characterisation of the active substance
The active substance, the enzyme fumonisin esterase (EC 3.1.1.87), partially degrades fumonisin
B1 (FB1) and related fumonisins by cleavage of the diester bonds and release of the tricarballylic acid
and is intended to reduce the toxicity of contaminated feed. The enzyme was identiﬁed in a
Sphingopyxis sp., an a-Proteobacterium isolated from soil, and the genes encoding the activity used to
transform a strain of the yeast Komagataella phafﬁi (formerly Pichia pastoris) which is then used as
the production organism.8
3.1.2. Characterisation of production organism
The additive is produced with a genetically modiﬁed strain of K. phafﬁi, which is deposited in the
German Collection of Microorganisms and Cell Cultures as P. pastoris with deposit number DSM
32159.9 The strain was identiﬁed as K. phafﬁi by sequence analysis of the 26S/28S and ITS regions of
the rRNA gene, and partial sequence of the EF-1a gene.10
3.1.2.1. Characteristics of the recipient or parental microorganism
The recipient strain is a genetically modiﬁed derivative of the parental strain K. phafﬁi CBS 7435
(NRRL Y-11430, ATCC 76273). The whole-genome sequence of this strain is published (K€uberl et al.,
2011). The strain was originally taxonomically classiﬁed as P. pastoris, a species which is considered by
EFSA to be suitable for the Qualiﬁed Presumption of Safety (QPS) approach to safety assessment
(EFSA BIOHAZ Panel, 2017) when used for enzyme production. Recently, this strain was renamed as K.
phafﬁi by molecular taxonomy analyses. The FEEDAP Panel considers that this reclassiﬁcation does not
have an impact in the safety status of the strain.
3.1.2.2. Characteristics of the donor organism
The fumD gene, coding for a FB1 carboxylesterase, is a codon-optimised synthetic sequence
based on the fumD gene of the a-proteobacterium Sphingopyxis sp. MTA144.12 This strain, which was
isolated from soil, carries a gene cluster associated with fumonisin degradation as described by Heinl
8 Technical Dossier/Section II/Annex II.19.
9 Technical Dossier/Section II/Annex II.20.
10 Technical Dossier/Supplementary Information/Annex (i).
12 Technical Dossier/Section II/Annex II.27.
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et al. (2010). The gene fumD codes for a carboxylesterase, which catalyses the hydrolysis of fumonisin
B1 to aminopentol 1 (producing fully de-esteriﬁed fumonisin, HFB1).
3.1.2.3. Description of the genetic modiﬁcation
3.1.3. Manufacturing process
Fumonisin esterase is produced by the submerged fermentation of the production strain. After
fermentation, the biomass is separated by centrifugation, and the supernatant is then micro- and
ultraﬁltered. The ﬁnal additive is prepared from the high-molecular weight material recovered from
ultraﬁltration mixed with 10% maltodextrin, which is then spray dried. The dried material is then
blended with maltodextrin.
FUMzyme® is routinely quality controlled for the presence/absence of cultivable K. phafﬁi, following
a speciﬁc procedure.17 The absence of viable cells of the production strain is tested in 25 g after a
resuscitation step in non-selective liquid medium at 37°C for 6–8 h, followed by plating 0.1 mL of the
suspension onto selective medium and incubating at 30°C for 48–96 h.18 No viable cells detected in
three batches analysed in triplicate.19 Recombinant DNA is also removed during downstream
processing: no recombinant DNA was detected in 100 mg of three batches of the ﬁnal product by
real-time PCR,
17 Technical dossier/Section II/Annex II.65.
18 Technical dossier/Section II/Annex II.66.
19 Technical Dossier/Supplementary Information/Annex (ii).
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3.1.4. Characterisation of the additive
The additive typically contains approximately 8% of material derived from the fermentation and
90% of the added maltodextrin carrier and has a speciﬁed minimum content of 3,000 U esterase/g.
One unit (U) is the enzymatic activity that releases 1 lmol propane-1,2,3-tricarboxylic acid per minute
from 100 lM FB1 in 20 mM Tris-Cl buffer pH 8.0 with 0.1 mg/mL bovine serum albumin at 30°C.
Compliance with this minimum speciﬁcation was demonstrated for ﬁve batches of the additive (mean
3,470 U/g, range 3,150–3,780 U/g additive).21
Routine monitoring for the presence of heavy metals and arsenic (As) in three different production
batches of the additive showed that the concentrations of lead (Pb), cadmium (Cd), mercury (Hg) and
As were in all cases below the respective limits of quantiﬁcation (Pb < 0.5, Cd < 0.1, Hg < 0.01 and
As < 0.5 mg/kg).22
Quality control parameters for microbial contaminants are set at a maximum of 30 colony-forming
units (CFU)/g for total coliforms, a maximum of 100 CFU/g individually for yeasts and ﬁlamentous
fungi and the absence of Escherichia coli and Salmonella spp. in 25 g product; certiﬁcates of analysis
for three batches of product show compliance with these values.23 A further three batches were
examined for the presence of 11 mycotoxins commonly associated with cereals24; all values were
below the limits of detection.25
Particle size analysis by laser diffraction (three batches) showed that approximately 60% of the
ﬁnal product had a particle size < 100 lm, 40% < 50 lm and ~ 5% of respirable size (< 10 lm).26
The dusting potential of the same three batches determined according to the Stauber–Heubach
method gave a mean value of 0.25 g/m3.27
3.1.5. Stability and homogeneity
3.1.5.1. Shelf-life
The shelf-life of the product was established using ﬁve batches of product stored at room
temperature or at 37°C for 18 months in sealed containers.28 Samples were analysed for activity at six
monthly intervals. There was essentially no loss of activity at room temperature after 18 months and
only a small loss at the higher temperature (10–15%).
3.1.5.2. Stability in premixes and feed
A single batch of the additive was mixed with a commercial bentonite mineral feed at 20,000 U/kg and
a commercial vitamin–mineral premix (containing choline chloride) to a concentration of 15,000 U/kg.29
The samples were then stored for 6 months at room temperature. No loss of activity of any signiﬁcance
was seen after 6 months storage under these conditions.
Four batches of feed (in mash form) containing the additive were prepared, the ﬁrst three based on
a grower diet for pigs supplemented with 10, 15 or 20 U/kg feed and the fourth on a feed for chickens
supplemented with 45 U/kg feed.30 Activity was measured at the time of preparation and again after
6 months storage at 22  2°C. Essentially no loss of activity was recorded.
3.1.5.3. Homogeneity
A single batch of additive was mixed with additional maltodextrin and then mixed with 99 kg piglet
feed using a farm-scale feed mill.31 The treated feed with an intended concentration of 450 U/kg feed
was then distributed equally to 10 bags and, from each bag, 10 subsamples were taken and analysed for
activity. The results showed a mean value of 477 U/kg feed with a coefﬁcient of variation (CV) of 3.6%.
21 Technical Dossier/Section II/Annex II.03.
22 Technical Dossier/Section II/Annexes II.03, II.05 and II.06.
23 Technical Dossier/Section II/Annexes II.08, II.09 and II.10.
24 Technical Dossier/Section II/Annex II.07.
25 Limits of detection (in µg/kg) are listed here. Deoxynivalenol: 20, zearalenone: 4, aﬂatoxin B1/B2/G1: 0.2, fumonisin B1/B2:
20, HT-2 toxin/T-2 toxin: 2.
26 Technical Dossier/Section II/Annex II.12.
27 Technical Dossier/Section II/Annexes II.13, II.14 and II.15.
28 Technical Dossier/Section II/Annex II.67.
29 Technical Dossier/Section II/Annex II.68.
30 Technical Dossier/Section II/Annex II.69.
31 Technical Dossier/Section II/Annex II.70.
Fumonisin esterase produced by Komagataella phafﬁi DSM 32159 for pigs and all avian species
www.efsa.europa.eu/efsajournal 7 EFSA Journal 2018;16(5):5269
3.1.6. Interference with the analysis of mycotoxins in feed
The possible interference of the additive in the determination of fumonisins in feedstuffs was
examined.32 The methanol/acetonitrile/water solution used for the initial extraction of fumonisins in the
standard method was found to fully inhibit the action of fumonisin esterase and, therefore, no
interference is expected. Given the speciﬁcity of the esterase, the analytical determination of other
structural classes of mycotoxins would not be affected.
3.1.7. Conditions of use
The additive is intended for use with pigs and poultry at a minimum inclusion rate of 10 U/kg
complete feed. No maximum incorporation rate is proposed. No withdrawal period is foreseen.
3.2. Safety
3.2.1. Safety aspects of the genetic modiﬁcation
The original strain from which the production organism was derived belong to K. phafﬁi, formerly
identiﬁed as P. pastoris, a species which is considered by EFSA to be suitable for the QPS approach to
safety assessment when used for enzyme production (EFSA BIOHAZ Panel, 2017). The FEEDAP
Panel considers that this reclassiﬁcation does not have an impact in the safety status of the strain. The
production strain carries several copies of the ZeocinTM resistance gene and the GeneticinTM resistance
gene integrated into its chromosome.
Neither the viable production strain nor its recombinant DNA was found in the ﬁnal product.
Therefore, the product FUMzyme®, manufactured by fermentation with K. phafﬁi DSM 32159, does
not give rise to safety concerns deriving from the genetic modiﬁcation of the production strain.
3.2.2. Toxicological studies
The toxicity studies were conducted with a non-standardised production batch in which the
proportion of the culture supernatant was greater than the standardised product resulting in higher
concentrations of the enzyme (8,650 U/g).
3.2.2.1. Genotoxicity
Bacterial reverse mutation test
Two independent experiments were made in compliance with the Organisation for Economic
Co-operation and Development (OECD) guideline 471, with the Salmonella Typhimurium strains
TA1535, TA1537, TA98, TA100 and TA102 with and without metabolic activation.33 Six doses were
tested, starting at 31.6 lg and increasing to a top dose of 5,000 lg. No precipitation of the test item
or toxic effects was seen. No increase in the number of revertant colonies was seen at any dose tested
in the presence or absence of metabolic activation. The additive is, therefore, considered non-
mutagenic under the conditions of the assay.
In vitro chromosome aberration test
This test was made according to the OECD guideline 473 using the Chinese hamster V79 cell line.34
Chromosomes were prepared 21 h after the start of treatment with the test item and 150 metaphases
per culture scored for structural chromosome aberrations. Treatment intervals were 4 h with and
without metabolic activation in experiment 1 and 4 h with activation and 20 h without activation in
experiment 2. The doses tested were 1,000, 1,500 and 2,000 lg/mL in both parts of the test. The
appropriate positive controls were included (ethyl-methanesulfonate and cyclophosphamide) which
behaved as expected. The test item did not induce structural chromosome aberrations in either
experiment and no increase in the frequency of polyploid cells was observed in comparison with the
negative control. The test item is thus considered non-clastogenic under the conditions of the test.
32 Technical Dossier/Section II/Annex II.71.
33 Technical Dossier/Section III/Annex III.34.
34 Technical Dossier/Section III/Annex III.35.
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In vivo mammalian erythrocyte micronucleus test
The test was made following OECD guideline 474 using mouse peripheral blood cells.35 Blood samples
were collected for analysis from 10 mice (strain NMRI; ﬁve males and ﬁve females) per treatment 44 and
66 h after a single administration of the test item. A maximum tolerated dose (MTD) of 2,000 mg/kg
body weight (bw) was selected on the basis of a preliminary range ﬁnding experiment with intermediate
doses of 1,000 and 400 mg/kg bw, representing 0.5 and 0.2 of the MTD. Animals given the two lower
doses showed no clinical symptoms. Those given the top dose showed slight signs of systemic toxicity.
For all doses, 10,000 polychromatic erythrocytes per animal were scored for the incidence of
micronucleated immature cells. Negative controls were within the historical data and the positive control
(cyclophosphamide) behaved as expected. No biologically relevant increase in micronucleated cells was
seen at any dose, from which it was concluded that the test item is non-mutagenic with respect to
clastogenicity and/or aneugenicity.
3.2.2.2. Repeated -dose 90-day oral toxicity study
A Good Laboratory Practice (GLP) compliant repeat dose study was made with equal numbers of
male and female Wistar rats following the protocol for OECD guideline 408.36 Animals were caged in
groups of ﬁve animals of the same sex. Twenty animals (two cages of each sex per treatment) were
assigned to each of a vehicular control and groups given daily 100, 1,000 and 2,000 mg/kg bw of the
test item via the feed for 90 days. A further satellite group of 10 animals was also given the high dose
for 90 days. Body weight was determined at the start and weekly thereafter and body condition
monitored daily. Blood samples were taken on day 90 from the control and high-dose groups for
haematology and clinical chemistry. A complete necropsy of all animals was made with histopathology
for tissues from the high-dose group. Animals in the satellite group were observed for a further 28
post-treatment days before necropsy on day 118.
No mortalities, behavioural changes or adverse clinical signs were noted during the study. Growth
of males and females was not signiﬁcantly different between the treatment groups. No statistically
signiﬁcant changes in clinical chemistry results were seen in either sex or in haematology results for
males. The only signiﬁcant difference observed was a change in the relative volume of lymphocytes in
female rats given the top dose compared to the control group. This change is reported as being within
the historical range for the colony. There were no signiﬁcant differences in relative or absolute organ
weights in male rats, but signiﬁcant differences were seen in the absolute weight of uterus and ovaries
and relative weight of ovaries. These changes were not dose related and were within historical values
and were attributed by the study authors to animals at different stages of their oestrus cycle.
3.2.2.3. Metabolites resulting from the degradation of fumonisins
Metabolites resulting from the complete or partial de-esteriﬁcation of fumonisins were assessed for
safety in the previous opinion on the use of a fumonisin esterase in pigs and found to be less toxic
than the parent mycotoxin (EFSA FEEDAP Panel, 2014). Since the action of the esterase on any
contaminating fumonisins will be essentially the same in the pig and poultry digestive tracts and
independent of the source of the enzyme, the previous assessment and its conclusion apply equally to
the present application.
3.2.3. Safety for the target species
The recipient strain K. phafﬁi used for the production of the enzyme is a species considered by
EFSA to be suitable for the QPS approach to the assessment of safety. Since the genetic modiﬁcations
give no cause for concern and since the enzyme itself has been assessed for safety in the context of
previous opinions, there is little reason to consider further target animal safety. However, the applicant
has chosen to provide four additional tolerance studies with weaned piglets, chickens and turkeys for
fattening and laying hens.
3.2.3.1. Safety for weaned piglets
A total of 96 weaned piglets (mixed sex O-HYB-F1 with mean start weight of approximately 10 kg)
were assigned to one of three groups: a control group and two test groups provided with the additive.
35 Technical Dossier/Section III/Annex III.36.
36 Technical Dossier/Section III/Annex III.37.
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Each treatment consisted of four replicate pens of eight animals.37 Since no recommended or
maximum inclusion level of the additive is proposed, the applicant selected 300 U/kg feed to represent
the likely maximum inclusion rate for the 91 group and an overdose group given 100-fold this value
(30,000 U/kg feed). Concentrations in feed were conﬁrmed by analysis; feed showed analytically to be
free of contaminating fumonisins. All animals were given a basal diet based on wheat, barley and
soybean in mash form for 42 days. Pigs were weighed at the start and at days 14, 28 and 42 and
average weight gain calculated; feed intake was measured for the corresponding periods. Feed intake
per animal and day and feed to gain calculated. The pen was used throughout as the experimental
unit. After a test for normal distribution (Shapiro–Wilk test), data were analysed by the analysis of
variance (ANOVA) or by the non-parametric Kruskal–Wallis test.
No mortalities were recorded. No signiﬁcant differences were found in any of the measured or
calculated parameters. Final weight was approximately 31 kg, weight gain 21 kg, feed intake 0.9 kg
per animal per day and feed to gain ratio 1.84.
3.2.3.2. Safety for chickens for fattening
A total of 600 one-day-old chicks (Ross 308, mixed sex) were distributed to the same three
treatment groups described above.38 Each treatment was allocated 10 replicate pens each with 20
birds per pen. Birds were given a basal starter and grower diets based on maize and soybean in mash
form which was shown to be essentially free of contaminating fumonisins. The duration of the study
was 35 days. Birds were weighed at the start of the study, after 14 days and at the end. Feed
consumption was measured over the corresponding periods, and from these data, weight gain and
feed to gain ratio were calculated. The statistical analysis applied was that described for the study in
weaned piglets, using the pen as experimental unit. Data analysis included tests for homogeneity of
variances (Levene’s test). Where variances were not homogeneous, ANOVA was replaced by a Welch
test. This was used in the analysis of feed to gain values.
No veterinary intervention was required during the study. Mortality was not reported. There were
no signiﬁcant differences in ﬁnal weight of birds (range: 1.71–1.80 kg) or feed intake (3.0 kg). Feed to
gain ratio appeared to be marginally improved in the two treated groups compared to control birds
(1.87 vs. 1.72 and 1.73, p = 0.097).
3.2.3.3. Safety for turkeys for fattening
A randomised block design was used involving a total of 360 female Hybrid Converter turkey poults
allocated to the same treatments groups as the previously described tolerance studies (0, 91 and
9100).39 However, analysis showed that the recovered enzyme activity was approximately 50% higher
than the intended level (i.e. 0, 9 1.5 and 9 150). Birds were allocated to 10 replicate pens of 12 female
animals per treatment group and fed a basal maize–soybean diet free of fumonisins for 42 days. Birds
were individually weighed at the start and on days 14, 28 and 42 and feed intake per pen measured for
the corresponding periods. Weight gain and feed to gain ratio were calculated from these data. All data
were subjected to an ANOVA, with least signiﬁcant difference used to compare treatment means when a
signiﬁcant difference was identiﬁed by ANOVA. The pen was the experimental unit.
Five birds died during the trial, but remaining birds were healthy and no veterinary intervention was
required. There were no signiﬁcant differences in any measured production parameter when control
birds were compared to those in the treatment groups. Final body weight was 2.1 kg, feed intake
~ 3.2 kg and feed to gain was within the range 1.55–1.60.
3.2.3.4. Safety for laying hens
Three groups of 260 laying hens (NovoBrown) were established with each group housed in 10
paired cages holding 26 hens.40 Treatments consisted of a control group given a basal diet of wheat
and sunﬂower cake in mash form and two treatment groups supplemented with either 300 (9 1) or
30,000 (9 100) U enzyme activity (conﬁrmed by analysis). Supplementation started when hens were
133 days of age with a 7-day acclimatisation period followed by an experimental period from 140 days
of age to 198 days of age (56 days observation). Mortality, feed consumption and egg production
were monitored throughout, body weight was measured on days 140, 168 and 198 and average egg
37 Technical Dossier/Section III/Annex III.01.
38 Technical Dossier/Section III/Annex III.13.
39 Technical Dossier/Section III/Annex III.28.
40 Technical Dossier/Section III/Annex III.22.
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size measured every 2 weeks. All eggs produced over a 24 h period were collected at days 140, 168
and 198 and examined for quality parameters (individual egg weight, shell strength, Haugh units). All
normally distributed data were subject to ANOVA, with the paired cage as the experimental unit for
production parameters and the egg for quality parameters; otherwise, a non-parametric Kruskal–Wallis
test was used.
Overall mortality was low (0.6%). No signiﬁcant differences were seen for any of the measured
parameters between the control group and either of the test groups. The laying rate and average egg
weight were normal for the beginning of lay (91% and 55 g). Cumulative egg numbers averaged 52.5
and cumulative egg mass 2.86 kg. Egg quality parameters were not affected by treatment.
3.2.3.5. Conclusions on safety for the target species
A value of 300 U/kg complete feed was selected by the applicant to represent a maximum use
level. This was the rate described as a recommended maximum use level in the two previous
applications for the same activity made by the same producer.
A 100-fold overdose of this maximum application rate was tolerated by weaned piglets, chickens
and turkeys for fattening and by laying hens and so the selected maximum rate of 300 U/kg feed can
be considered safe for these species/categories, with a wide margin of safety.
This conclusion can also be directly applied to all pigs, chickens reared for laying and turkeys
reared for breeding and extrapolated to all other poultry species for growing and laying and to minor
porcine species at the same maximum application rate of 300 U/kg feed without a need for further
studies.
3.2.4. Safety for the consumer
The production organism is considered suitable for the QPS approach to safety assessment. Taking
into account the nature of the genetic modiﬁcation and the extensive puriﬁcation undertaken to
exclude DNA fragments from the ﬁnal additive, the production or retention of toxic metabolites
produced during fermentation is considered improbable. This was conﬁrmed by the results of two
in vitro and one in vivo tests for genotoxicity and a subchronic oral toxicity study. No evidence of
mutagenicity or genotoxicity was detected and no evidence of toxicity found in the oral toxicity study.
Metabolites resulting from the complete or partial de-esteriﬁcation of fumonisins have been
previously assessed for safety and found to be less toxic than the parent mycotoxin. The action of
fumonisin esterase on any contaminating fumonisins will be independent of source and essentially the
same in pig and poultry digestive tracts and will act to reduce any toxic load. Consequently, the use of
the additive in pigs and poultry will not introduce hazards for consumers.
3.2.5. Safety for the user
3.2.5.1. Effects on the respiratory system
An acute inhalation toxicity study in rats was made following the OECD guideline 403.41 This
involved a single nose-only application followed by observation over the next 14 days. Rats recovered
from an initial irregular respiration within 24 h; thereafter, no adverse ﬁndings were observed. The
LC50 derived from for this test was > 5.17 mg/L, the highest concentration tested.
Although exposure to the additive via respiration is likely to be low – the additive has a low-dusting
potential with approximately 5% of particles having a diameter of respirable size (< 10 lm) – given
the results of the skin sensitisation test (see Section 3.2.5.2.) and the proteinaceous nature of the
additive, sensitisation via respiratory route cannot be excluded.
3.2.5.2. Effects on skin and eyes
An acute dermal toxicity study was made with the additive following OECD guideline 402.42 A single
limit dose of 2,000 mg/kg bw was applied over a 24 h period followed by 14 days observation. No local
dermal or general clinical signs were observed. The LD50 derived from this test was > 2,000 mg/kg bw.
The acute study was followed by skin and eye irritation studies following OECD guidelines 404 and 405.
All adverse dermal responses were fully reversed within 1 h of patch removal and all effects on the eye
reversed within 24 h. The additive is considered non-irritant to skin and eyes.
41 Technical Dossier/Section III/Annex III.42.
42 Technical Dossier/Section III/Annex III.33.
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The capacity to induce dermal sensitisation was tested in a maximisation test with guinea pigs
(OECD guideline 406).43 The test item caused mild erythema in 2/10 animals in the test group (0/10 in
the control group) identiﬁed as sensitisation at the tested concentration. According to the EC criteria
on classiﬁcation, labelling and packaging of substances and mixtures (Guidelines in Regulation (EC)
No 1272/2008)44 labelling as a sensitiser is not necessary, as the percentage of sensitised animals was
less than 30%.
3.2.5.3. Conclusions on safety for the user
The additive is not toxic by inhalation and the respiratory exposure is likely to be low; however, a
risk of sensitisation via the respiratory route cannot be excluded. The additive is non-irritant to skin
and eyes and is not considered as a dermal sensitiser.
3.2.6. Safety for the environment
Neither the viable production strain nor its recombinant DNA was found in the ﬁnal product.
Therefore, the product FUMzyme®, manufactured by fermentation with K. phafﬁi DSM 32159, does not
give rise to environmental safety concern deriving from the genetic modiﬁcation of the production strain.
The active substance of the additive, fumonisin esterase, is a protein and as such will be largely
degraded/inactivated during the passage through the digestive tract of animals. In addition, any
hydrolysis of fumonisins in the digestive tract would simply anticipate that which would occur naturally
in soils. Therefore, no risks for the environment are expected following the use of the additive in feeds
under the proposed conditions of use.
3.3. Efﬁcacy
The European Commission has set guidance values for the presence of fumonisins in
complementary and complete feedingstuffs of 5 mg/kg for pigs and 20 mg/kg for poultry (Commission
Recommendation 2006/576/EC45). These advisory limits are set at a level intended to protect the
animal from any adverse effects. Consequently, efﬁcacy studies which respect these limits would not
be expected to demonstrate an improvement in performance. Although performance characteristics
were monitored in all of the efﬁcacy studies, the FEEDAP Panel uses such data only to conﬁrm that
animals on trial behaved as expected.
In the previous applications assessed by the FEEDAP Panel with this enzyme, a minimum efﬁcacious
supplementation rate of 15 U/kg feed was established for pigs and poultry (EFSA FEEDAP Panel, 2014,
2016). The applicant has now provided additional efﬁcacy studies with a reduced minimum
supplementation rate of 10 U/kg feed as proposed in the conditions of use (see also Section 3.1.7).
3.3.1. Efﬁcacy for chickens for fattening
A total of 480 mixed sex Ross 308 chicks were distributed to one of three treatment groups.46 Eight
ﬂoor pens of 20 birds were used for each treatment group: a control group fed a basal mash diet
based on maize and soybean for a 21-day period (day 14–35 of life), a second group fed the same
diet deliberately contaminated with fumonisins B1/B2 (FB2) at an intended concentration of 15 mg/kg
feed and a test group fed the same contaminated feed supplemented with the additive at 10 U/kg
feed. The concentration of fumonisins and enzyme was conﬁrmed by analysis. Performance
characteristics were measured and a pooled faecal sample collected from each pen at the end of the
study for analysis of fumonisins and their metabolites.
Data were checked for normal distribution (Shapiro–Wilks test). Results of the faecal analysis were
found to be non-normally distributed. Since neither fumonisins or enzyme was to be expected in the
control group, a paired comparison was made between samples from birds given the contaminated
feed and those given the contaminated treated feed using a Mann–Whitney U test. Results of the
faecal analysis are shown in Table 1.
43 Technical Dossier/Section III/Annex III.45.
44 Regulation (EC) No 1272/2008 of the European Parliament and of the council of 16 December 2008 on classiﬁcation, labelling
and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending
Regulation (EC) No 1907/2006, OJ L 353, 31.12.2008, p.1
45 Commission Recommendation of 17 August 2006 on the presence of deoxynivalenol, zearalenone, ochratoxin A, T-2 and HT-2
and fumonisins in products intended for animal feeding. OJ L 229, 23.8.2006, p. 7.
46 Technical Dossier/Section IV/Annex IV.12.
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Inclusion of the additive signiﬁcantly reduced the concentration of FB1 in faeces with a concomitant
increase in partially hydrolysed fumonisin (pHFB1a and b) and fully de-esteriﬁed fumonisin (HFB1).
3.3.2. Efﬁcacy for laying hens
A 14-day trial with 120 laying hens (Lohmann Brown, 25 weeks of age at start) was designed with
three experimental groups: a control group fed a basal diet, a group given the basal diet deliberately
contaminated with FB1/FB2 and a test group receiving the contaminated diet supplemented with the
enzyme at 10 U kg feed.47 The contaminated feed contained approximately 8 mg fumonisin per kg
feed. A total of 30 pens each holding four hens were used with 10 pens randomly allocated to a
treatment. The basal diet was based on wheat, maize and soybean and was provided ad libitum in
mash form. Birds were weighed at the start and end of the study and eggs counted and weighed daily.
A single-pooled faecal sample was collected from each pen at the start, on day 7 and on day 14.
Performance characteristics were statistically treated as in the trial described above. The results for
faecal FB1 content was analysed using a Kruskal–Wallis pairwise test and the metabolites using a
Mann–Whitney U test as above. Results of the faecal analysis are shown in Table 2.
Essentially the same pattern of results was seen with the laying hen as with the chickens. Although
the reduction in FB1 seen after both 7 and 14 days did not reach signiﬁcance, the concentration of the
fully de-esteriﬁed fumonisin was signiﬁcantly increased at both time points.
3.3.3. Efﬁcacy for weaned piglets
Three studies could be assessed, involving only a limited number of animals are described, two
made within the European Union (EU) and the third elsewhere.
In the ﬁrst study, a total of 18 piglets (28 days of age, start weight 7.6 kg, O-HYB-F10, nine of
each sex) was distributed between six pens of three animals.48 Two pens were assigned to each of
three treatments: a control group fed a diet consisting of a mash feed based on wheat–soy–barley, a
Table 1: Effect of fumonisin esterase on the concentration of fumonisin B1 and its metabolites (ng/g)
in faeces of chickens for fattening after 21 days
Parameter(a)
Control
group
Contaminated
group (a)
Treated contaminated
group (b)
p value
a vs. b
FB1 346 41,593 15,330 < 0.001
pHFB1a 23 319 832 < 0.001
pHFB1b 26 423 2,600 < 0.001
HFB1 99 84 5,341 < 0.001
(a): FB1: fumonisin B1; pHFB1a, pHFB1b: partially hydrolysed fumonisin; HFB1: fully de-esteriﬁed fumonisin.
Table 2: Effect of fumonisin esterase on the concentration of fumonisin B1 and its metabolites (ng/g)
in faeces of laying hens after seven and 14 days
Parameter(a) Control group
Contaminated
group (a)
Treated contaminated
group (b)
p value
a vs. b
After 7 days
FB1 120 11,075 4,291 0.136
pHFB1a 7 2,043 560 0.050
pHFB1b 8 2,831 1,205 0.008
HFB1 21 989 3,370 0.003
After 14 days
FB1 132 9,507 4,807 0.108
pHFB1a 7 1,275 609 0.029
pHFB1b 8 2,158 1,318 0.019
HFB1 21 787 3,550 < 0.001
(a): FB1: fumonisin B1; pHFB1a, pHFB1b: partially hydrolysed fumonisin; HFB1: fully de-esteriﬁed fumonisin.
47 Technical Dossier/Section IV/Annex IV.01.
48 Technical Dossier/Section IV/Annex IV.22.
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group given a mash feed naturally contaminated with 3.5 mg/kg FB1 and FB2 and a third group given
the contaminated feed supplemented with 6 U of the fumonisin esterase/kg feed. The study lasted
42 days. Blood samples were taken from each animal at the end of the study and analysed for
sphinganine/sphingosine ratio (Sa/So), considered a sensitive marker of fumonisin toxicity. A single
faecal sample was also collected from each pig at the end of the study following a ‘spontaneous
defecation’. However, since the pen is considered the experimental unit, a statistical analysis of the
faecal data could not be made. The results of the Sa/So ratio are shown in Table 3.
The second study involved eight individually penned piglets (20 days of age, start weight ~ 6 kg,
four males and four females).49 Four piglets were given a maize and soybean mash feed naturally
contaminated with 2 mg FB1 and FB2/kg feed. The second group of four were given the same feed
supplemented with the additive at 10 U/kg feed. The study lasted 42 days. Blood and faecal samples
were collected from all animals on days 14, 28 and 42. Blood was analysed for serum Sa/So ratio and
faecal samples for fumonisin and its metabolites. Results were examined for normality (Shapiro–Wilks
test) and the means of those found normally distributed compared using a Student t-test and those
not normally distributed were compared using a Mann–Whitney U test. Results are summarised in
Table 3.
The third study was a near duplicate of the ﬁrst (described above) and was made at the same
location.50 Again 18 mixed sex weaned piglets were used distributed to the same number of pens (six)
with two pens used for each of the three treatments. Animals were 6 weeks of age at the start with a
mean weight of 11.5 kg. In this case, the intended level of contamination with FB1 and FB2 was
5 mg/kg feed with the test group supplemented with 10 enzyme U/kg feed. The study lasted 41 days.
Blood and faecal samples were collected on days 14, 28 and 41. Blood was analysed for serum Sa/So
ratio and faecal samples for fumonisin and its metabolites. As previously, since the number of
replicates did not allow a statistical analysis, the faecal data were not considered. Sa/So ratio data
were compared using Mann–Whitney U test. Results are shown in Table 3.
The Sa/So ratio was signiﬁcantly reduced in the treated group in all three studies with values
similar to those of the control group given the feed essentially free of fumonisins (where this was
measured, studies 1 and 3). In the single study with sufﬁcient replication to allow a statistical
consideration of the faecal concentration of fumonisins and metabolites, the pattern of effect on the
fumonisin-contaminated feed by the enzyme was essentially that seen in poultry. The FB1
concentration in faeces was signiﬁcantly reduced while that of the de-esteriﬁed fumonisin (HFB1) was
signiﬁcantly increased.
Table 3: Effect of fumonisin esterase on the serum sphinganine/sphingosine ratio (Sa/So) and the
concentration of fumonisin B1 and its metabolites (lg/g) in faeces of weaned piglets
Parameter(a)
Control
group
Contaminated
group (a)
Treated contaminated
group (b)
p value
a vs. b
Study 1
Sa/So ratio (42 days) 0.15 0.28 0.16 0.005
Study 2
Sa/So ratio (28 days) – 0.27 0.19 0.038
Sa/So ratio (42 days) – 0.27 0.22 0.076
FB1 (42 days) – 5.76 0.37 0.010
pHFB1a (42 days) – 1.01 0.40 0.210
pHFB1b (42 days) – 0.69 0.47 0.487
HFB1 (42 days) – 0.11 2.60 0.029
Study 3
Sa/So ratio (14 days) 0.14 0.16 0.13 0.045
Sa/So ratio (28 days) 0.14 0.25 0.14 0.003
Sa/So ratio (41 days) 0.13 0.21 0.14 0.021
(a): Sa/So: sphinganine/sphingosine ratio; pHFB1a, pHFB1b: partially hydrolysed fumonisin; HFB1: fully de-esteriﬁed fumonisin.
49 Technical Dossier/Section IV/Annex IV.33.
50 Technical Dossier/Section IV/Annex IV.42.
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3.3.4. Enzyme speciﬁcity
A number on in vitro studies made with FB1 considered in the previous opinions of the FEEDAP
Panel showed that the action of fumonisin esterase resulted in partial or complete de-esteriﬁcation,
releasing tricarballylic acid and the fully or partially de-esteriﬁed aminopentol backbone (EFSA FEEDAP
Panel, 2014, 2016). Although FB1 and FB2 are the most prevalent fumonisins, a total of eight are
recognised differing only by the number and position of hydroxyl groups on the aminopentol
backbone. However, since all fumonisins possess tricarballylic substituents on carbons 6 and 7 and
since the presence of the hydroxyls are insufﬁciently bulky to affect enzyme binding or catalytic
activity, the enzyme will be equally effective in its action against all recognised fumonisins.
3.3.5. Conclusions on efﬁcacy
The additive has the capacity to degrade fumonisin contaminants in feed of marketable quality when
used at the minimum recommended dose of 10 U/kg complete feed, as shown in studies with chickens for
fattening, laying hens and weaned piglets. This conclusion is based on a reduced fumonisin faecal excretion
accompanied by an increased excretion of de-esteriﬁed fumonisin (in one study each in chickens for
fattening, laying hens and piglets) and the smaller Sa/So ratio in serum (in three studies in piglets). Since
the mode of action of the additive can be reasonably assumed to be the same in animal species for which
the application is made, the FEEDAP Panel considers the additive as efﬁcacious for all poultry and all pigs.
The conclusion on efﬁcacy was drawn considering also the established efﬁcacy assessed in previous
applications of the same enzyme.
3.4. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation51 and Good
Manufacturing Practice.
4. Conclusions
Neither the viable production strain nor its recombinant DNA was found in the ﬁnal product.
Therefore, the product FUMzyme®, manufactured by fermentation with K. phafﬁi DSM 32159, does
not give rise to safety concern deriving from the genetic modiﬁcation of the production strain.
An application rate of 300 U/kg feed is safe for weaned piglets, chickens and turkeys for fattening
and laying hens with a wide margin of safety. This conclusion can also be directly applied to all pigs,
chickens reared for laying and turkeys reared for breeding and extrapolated to all other poultry species
for growing and laying and to minor porcine species at the same maximum application rate of 300 U/kg
feed without a need for further studies.
The use of the additive in pigs and in poultry under the conditions speciﬁed will not introduce
hazards for consumers.
The additive is not toxic by inhalation and the respiratory exposure is likely to be low; however, a
risk of sensitisation via the respiratory route cannot be excluded. The additive is non-irritant to skin
and eyes and is not considered as a dermal sensitiser.
No risks for the environment are expected following the use of the additive in feeds under the
proposed conditions of use.
The additive has the capability to degrade fumonisins in feed of marketable quality fed to poultry
and pigs when used at the minimum recommended dose of 10 U/kg complete feed.
Documentation provided to EFSA
1) FUMzyme® all pigs and all avian species. January 2017. Submitted by Biomin GmbH
2) FUMzyme® all pigs and all avian species. Supplementary information. August 2017.
Submitted by Biomin GmbH.
3) Evaluation report of the European Union Reference Laboratory for Feed Additives on the
Method(s) of Analysis for fumonisin esterase (EC 3.1.1.87) (FUMzyme®).
4) Comments from Member States.
51 Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements for
feed hygiene. OJ L 35, 8.2.2005, p. 1.
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As Arsenic
ATCC American Type Culture Collection
BIOHAZ EFSA Panel on Biological Hazards
bw Body weight
CBS Centraalbureau voor Schimmelcultures
Cd Cadmium
CFU Colony Forming Units
CV Coefﬁcient of variation
DNA deoxyribonucleic acid
DSM DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen
EURL European Union Reference Laboratory
FB1 fumonisin B1
FB2 fumonisin B2
FEEDAP Panel on Additives and Products or Substances used in Animal Feed
GLP Good Laboratory Practices
GM Genetically Modiﬁed
HFB1 fully de-esteriﬁed fumonisin
Hg Mercury
MTD maximum tolerated dose
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No Number
NRRL Agricultural Research Service Culture Collection, National Center for Agricultural Utilization
Research
OECD Organisation for Economic Co-operation and Development
Pb Lead
PCR polymerase chain reaction
pHFB1 partially de-esteriﬁed fumonisin
QPS Qualiﬁed Presumption of Safety
rRNA Ribosomal ribo nucleic acid
Sa sphinganine
So sphingosine
U Unit of activity
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Annex A – Executive Summary of the Evaluation Report of the European
Union Reference Laboratory for Feed Additives on the Method(s) of
Analysis for fumonisin esterase (EC 3.1.1.87) (FUMzyme®)
In the current application, authorisation is sought under article 4(1) for FUMzyme® under the
category/functional group 1(m) ‘technological additives’/’substances for reduction of the contamination of
feed by mycotoxins’, according to the classiﬁcation system of Annex I of Regulation (EC) No 1831/2003.
The authorisation is sought for the use of the feed additive for all pigs and all avian species. FUMzyme® is
used for its ability to degrade fumonisin B1. The enzyme detoxiﬁes this mycotoxin by cleavage of the
toxin’s diester bonds and removal of the propane-1,2,3-tricarboxylic acid side chains. According to the
applicant, the active substance in FUMzyme® is fumonisin esterase (EC 3.1.1.87) which is added to a
maltodextrin carrier to result in a minimum guaranteed enzyme activity of 3,000 U/g. The applicant
deﬁned the enzyme activity unit (U) as follows:
One unit (U) is the enzymatic activity that releases 1 lmol propane-1,2,3-tricarboxylic acid per
minute from 100 lM fumonisin B1 in 20 mM Tris-Cl buffer pH 8.0 with 0.1 mg/mL bovine serum
albumin at 30°C.
FUMzyme® is intended to be used in premixtures and feedingstuffs, with a proposed enzyme
activity ranging from 1052 to 300 U/kg feedingstuffs.
For the quantiﬁcation of the fumonisin esterase activity in the feed additive and feedingstuffs, the
applicant proposed a single laboratory validated and further veriﬁed method based on high-
performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS). The
method is based on the quantiﬁcation of the propane-1,2,3-tricarboxylic acid released from the action
of the enzyme on fumonisin B1.
For the quantiﬁcation of the enzyme activities in premixtures, the applicant suggested to dilute
premixture samples with animal feed (according to the recommended inclusion rate) and analyse them
applying the method for feedingstuffs mentioned above.
Based on the experimental evidence available the EURL recommends for ofﬁcial control the HPLC-
MS/MS method submitted by the applicant for the quantiﬁcation of the fumonisin esterase activity in
the feed additive, premixtures and feedingstuffs.
Further testing or validation of the methods to be performed through the consortium of National
Reference Laboratories as speciﬁed by Article 10 (Commission Regulation (EC) No 378/2005, as last
amended by Regulation (EU) 2015/1761) is not considered necessary.
52 This ﬁgure has been corrected by EFSA, as there was identiﬁed a typo error.
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